This study investigated the safety and effectiveness of upadacitinib (Rinvoq) in patients with rheumatoid arthritis (RA) who progressed after methotrexate (Otrexup). Researchers suggested that upadacitinib improved clinical and functional outcomes in these patients.

This study investigated the safety and effectiveness of peficitinib (Smyraf) in patients with unresponsive rheumatoid arthritis (RA). 

They found that this treatment reduced RA symptoms and was well tolerated in these patients.

This study investigated the effectiveness of filgotinib (FGB) in patients with unresponsive rheumatoid arthritis (RA).

They found that FGB improves RA management at 12 weeks. 

This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC).

They found that alpelisib significantly improved survival in patients with PIK3CA mutations. 

This study investigated the safety and effectiveness of long-term treatment with baricitinib (Olumiant) in rheumatoid arthritis (RA).  

They found that this drug was effective and well tolerated alone or in combination with methotrexate (MTX). 

This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment.

This study investigated if there is a link between frailty and fracture (breaking of a bone) risk in rheumatoid arthritis (RA). 

They found that patients with higher frailty were more likely to have bone fractures.  

This phase 3 trial will investigate the effect of bupropion (Wellbutrin) to treat fatigue in patients with breast cancer (BC).

The main outcomes will be fatigue, quality of life and depression. This trial is recruiting across the United States. 

This study wanted to find out how well patients with hormone-receptor-positive breast cancer survived when treated with ribociclib (Kisqali) added to endocrine therapy. The study found that patients treated with this treatment combination had longer survival compared to endocrine therapy alone.

This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States.